Cargando…
Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019
ABSTRACT: BACKGROUND: Recent patent losses for antiretroviral drugs (ARV) have led to the debate of cost-saving through the replacement of patented drugs with generic drugs. The split of recommended single-tablet regimens (STR) into their single substance partners is one of the considerations mentio...
Autores principales: | Lottes, Matthäus, Bremer, Viviane, Prugger, Christof, Kollan, Christian, Schmidt, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756633/ https://www.ncbi.nlm.nih.gov/pubmed/35027062 http://dx.doi.org/10.1186/s12913-021-07390-4 |
Ejemplares similares
-
Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort
por: Stoll, Matthias, et al.
Publicado: (2011) -
Estimating Savings Opportunities From Therapeutic Substitutions of High-Cost Generic Medications
por: Socal, Mariana P., et al.
Publicado: (2022) -
Minimally important difference in cost savings: Is it possible to identify an MID for cost savings?
por: Dooley, Mary, et al.
Publicado: (2021) -
Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?
por: Knoll, Stefanie, et al.
Publicado: (2013) -
Prevention is life- and cost-saving
por: Baussano, Iacopo, et al.
Publicado: (2020)